1.
Plasma Biomarkers of Inflammation, Endothelial Function and Hemostasis in Cerebral Small Vessel Disease
by Wiseman, Stewart J
Cerebrovascular diseases (Basel, Switzerland), 2015, Vol.40 (3-4), p.157-164
2.
The Johann Jacob Wepfer Award 2015 of the European Stroke Conference to Professor Ralph L. Sacco
Cerebrovascular diseases (Basel, Switzerland), 2015, Vol.40 (3-4), p.101-101
3.
Blood Markers of Coagulation, Fibrinolysis, Endothelial Dysfunction and Inflammation in Lacunar Stroke versus Non-Lacunar Stroke and Non-Stroke: Systematic Review and Meta-Analysis
by Wiseman, Stewart
Cerebrovascular diseases (Basel, Switzerland), 2014, Vol.37 (1), p.64-75
4.
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
by WISEMAN, G. A
European journal of nuclear medicine, 2000, Vol.27 (7), p.766-777
5.
Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's...
by Schilder, Russell
Cancer biotherapy & radiopharmaceuticals, 2004, Vol.19 (4), p.478-481
6.
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
by WISEMAN, Gregory A
Cancer biotherapy & radiopharmaceuticals, 2003, Vol.18 (2), p.165-178
8.
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's...
by Schilder, Russell
Cancer biotherapy & radiopharmaceuticals, 2004, Vol.19 (4), p.478-481
9.
Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
by Wiseman, Gregory A.
European journal of nuclear medicine and molecular imaging, 2000, Vol.27 (7), p.766-777
